GENERAl, R.R.O. 1990, Reg. 935
Section 8
Cite as GENERAl, R.R.O. 1990, Reg. 935, s. 8 · current to November 11, 2026 · consolidated from March 7, 2024 · read from e-Laws on November 16, 2026
The text
(1) The following conditions must be met in order for a drug product that has been designated as interchangeable to continue to be designated as interchangeable:
1. The manufacturer of the product shall give the executive officer notice of any change made to the product, including a formulation change, and of any change in the ownership of the manufacturer.
2. The product must be authorized for sale under the Food and Drugs Act (Canada).
3. The manufacturer of the product must continue to be able to supply the product at the drug benefit price in a quantity that is sufficient to meet the demand for the product where the product is designated as a listed drug product under the Ontario Drug Benefit Act.
4. If the product is a listed drug product under the Ontario Drug Benefit Act, the manufacturer shall not sell the product at a price higher than the drug benefit price permitted under that Act whether or not the product is supplied for the purposes of that Act.
5. Revoked: O. Reg. 221/10, s. 4 (3).
5.1, 5.2 Revoked: O. Reg. 221/10, s. 4 (1).
6. Revoked: O. Reg. 221/10, s. 4 (3).
7. If the drug product has not been designated as a listed drug product under the Ontario Drug Benefit Act, the manufacturer of the product shall give the executive officer notice of every change in the manufacturer’s list price for the drug product.
8. The manufacturer must not have provided a rebate as defined in subsection 12.1 (14) of the Act to a person listed in subsection 12.1 (1) of the Act with respect to the product contrary to the Act since Health Canada approved the product for sale in Canada.
9. If required by the executive officer, the manufacturer of a product that has been designated as interchangeable shall inform the executive officer of the price that the manufacturer receives for the product, net of the value of any ordinary commercial terms. O. Reg. 28/97, s. 3; O. Reg. 458/06, s. 5 (1-4); O. Reg. 558/06, s. 3 (1, 2); O. Reg. 321/07, s. 2 (1-4); O. Reg. 354/08, s. 2 (1-3); O. Reg. 221/10, s. 4 (1-4); O. Reg. 221/10, s. 4 (5).
(2) For greater certainty, the conditions set out in subsection (1) apply whether the designation of the product as an interchangeable product took place before, on or after July 1, 2010. O. Reg. 458/06, s. 5 (5); O. Reg. 221/10, s. 4 (6).
(3) Revoked: O. Reg. 221/10, s. 4 (7).
(4) Revoked: O. Reg. 221/10, s. 4 (9).
Read the GENERAl on e-Laws ↗
Made under Drug Interchangeability and Dispensing Fee Act, R.S.O. 1990, c. P.23.